Advanced search
Publication Cover
Expert Review of Hematology Volume 17, 2024 - Issue 7
Submit an article Journal homepage
808
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Is 50 mg/day the new standard dose of dasatinib in newly diagnosed patients with chronic myeloid leukemia in chronic phase?

Betül Saydana Faculty of Medicine, Ankara University, Ankara, TurkeyView further author information
,
Deniz Özmenb Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TurkeyView further author information
&
Ahmet Emre Eşkazanb Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9568-0894View further author information
ORCID Icon
Pages 275-277 | Received 10 Apr 2024, Accepted 17 Jun 2024, Published online: 25 Jun 2024

References

  • Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362(24):2260–2270. doi: 10.1056/NEJMoa1002315
  • Shah NP, Bhatia R, Altman JK, et al. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(1):43–69. doi: 10.6004/jnccn.2024.0007
  • Keskin D, Sadri S, Eskazan AE. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Des Devel Ther. 2016;10:3355–3361. doi: 10.2147/DDDT.S85050
  • Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34(20):2333–2340. doi: 10.1200/JCO.2015.64.8899
  • Naqvi K, Jabbour E, Skinner J, et al. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2018;124(13):2740–2747. doi: 10.1002/cncr.31357
  • Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2020;126(1):67–75. doi: 10.1002/cncr.32504
  • Gener-Ricos G, Haddad FG, Sasaki K, et al. Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk. 2023;23(10):742–748. doi: 10.1016/j.clml.2023.05.009
  • Jabbour E, Sasaki K, Haddad FG, et al. Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: a propensity score analysis. Am J Hematol. 2022;97(11):1413–1418. doi: 10.1002/ajh.26689
  • Murai K, Ureshino H, Kumagai T, et al. Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2021;8(12):e902–e911. doi: 10.1016/S2352-3026(21)00333-1
  • Imamura M, Nakamura Y, Hidaka D, et al. Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapy. Leuk Res Rep. 2024;21:100452. doi: 10.1016/j.lrr.2024.100452
  • Shin H, Ha JE, Zang DY, et al. Appropriate starting dose of dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2021;21(6):e521–e529. doi: 10.1016/j.clml.2021.01.020
  • Jabbour E, Haddad FG, Sasaki K, et al. Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia. Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317 Epub ahead of print.
  • Iurlo A, Cattaneo D, Artuso S, et al. Treatment-free remission in chronic myeloid leukemia patients treated with low-dose tkis: a feasible option also in the real-life a campus CML study. Front Oncol. 2022;12:839915. doi: 10.3389/fonc.2022.839915
  • Eskazan AE. Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: less is more, or is it? Cancer. 2018;124(21):4260–4261. doi: 10.1002/cncr.31682
  • Eskazan AE, Soysal T, Ongoren S, et al. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011;96(3):e15; author reply e16-7. doi: 10.3324/haematol.2011.040048

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.